⁸⁹Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging

<b>Background:</b> The ⁸⁹Zr radioisotope is increasingly vital in positron emission tomography (PET), especially immuno-PET, due to its long half-life of 78.4 h, allowing extended tracking of biological processes. This makes it particularly suitable for researching medicines with slow pha...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Maria-Roxana Tudoroiu-Cornoiu, Radu Marian Șerban, Diana Cocioabă, Dragoș Andrei Niculae, Doina Drăgănescu, Radu Leonte, Alina Catrinel Ion, Dana Niculae
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-06-01
Serija:	Pharmaceutics
Teme:	zirconium-89 pharmacokinetics radiopharmaceuticals HER2-positive affibody breast cancer
Online dostop:	https://www.mdpi.com/1999-4923/17/6/739
Oznake:	Označite Brez oznak, prvi označite!